In a surprising development, bonds tied to the Maryland Proton Treatment Center were recently traded at an astoundingly low price. This trade highlights the financial struggles faced by the center, which is one among several proton treatment facilities financed through unrated municipal bonds. The center has missed payments and faces doubts about its operational sustainability. Despite the advanced nature of proton therapy, which minimizes damage to surrounding tissues compared to other radiation treatments, these centers have struggled with attracting sufficient patient numbers to sustain bond payments.
A Burst of Activity Amid Financial Troubles
On a crisp spring day in April, there was an unexpected flurry of activity concerning the Maryland Proton Treatment Center's bonds. Approximately six tranches, each valued at $1 million, were traded at a mere five cents, according to records on the Electronic Municipal Market Access website. Originally issued in August 2018 by the Public Finance Authority Wisconsin for the Maryland Proton Treatment Center LLC, these bonds had an initial price of 75 cents and carry an 8.5% coupon, maturing in 2049.
This minimal recovery value astonishes seasoned high-yield investors, considering the substantial medical equipment and infrastructure involved. The lack of accessible offering documents on EMMA adds further opacity to what collateral, if any, backs these subordinate bonds. Previously, in July 2020, nearly $2 million of these bonds traded at 60 cents. However, much of the center's senior and junior bonds remain stagnant in the secondary market, reflecting broader challenges within the sector.
The Maryland Proton Treatment Center, among the pioneering facilities for this specialized cancer treatment, opened in 2015 with a significant issuance of $363.8 million in unrated bonds. Following difficulties in building patient volume, it underwent a debt restructuring in 2018, issuing $277.4 million in tax-exempt bonds via Wisconsin’s Public Finance Authority. Many high-yield bond buyers, including Robert Lind of Lind Capital Partners LLC, have steered clear of this sector due to inherent risks and concerns over financing current medical technology with long-term debt.
Proton therapy, though precise and beneficial, remains expensive and isn't universally covered by insurance, exacerbating financial pressures on such centers reliant on patient revenue.
From a journalistic perspective, this story underscores the complexities and risks associated with financing specialized medical facilities using long-term debt instruments. It serves as a cautionary tale about aligning technological advancements with appropriate financial strategies. For readers, it offers insight into the delicate balance between cutting-edge medical treatments and sustainable economic models, emphasizing the importance of thorough risk assessment in investments.
